GEN-3017 is under clinical development by Genmab and currently in Phase II for T-Cell Lymphomas. According to GlobalData, Phase II drugs for T-Cell Lymphomas have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GEN-3017’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GEN-3017 overview

GEN-3017 (DuoBody-CD3xCD30) is under development for the treatment of Hodgkin lymphoma and t-cell lymphoma. The therapeutic candidate is a Fc-silenced IgG1 bi-specific monoclonal antibody T-cell engager, created by controlled Fab-arm exchange of a humanized CD3 epsilon and a human CD30 monoclonal antibody. It is being developed based on DuoBody platform. It is administered through subcutaneous route.

Genmab overview

Genmab is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company’s marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan and the US. Genmab is headquartered in Copenhagen, Denmark.

For a complete picture of GEN-3017’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.